Clovis Oncology Inc. | Mutual Funds
Mutual Funds that own Clovis Oncology Inc.
SPDR S&P Biotech ETF
1,677,627
3.19%
4,317
1.02%
09/06/2018
Vanguard Small Cap Index Fund
1,254,977
2.38%
15,964
0.05%
07/31/2018
Vanguard Total Stock Market Index Fund
1,250,356
2.38%
1,196
0.01%
07/31/2018
Fidelity Select Biotechnology Portfolio
1,086,770
2.06%
52,791
0.42%
07/31/2018
FTIF SICAV - Franklin Biotechnology Discovery Fund
1,085,800
2.06%
0
1.67%
06/30/2018
iShares Russell 2000 ETF
1,000,959
1.9%
-534
0.07%
09/06/2018
Carmignac Patrimoine
942,955
1.79%
0
0.21%
06/29/2018
Vanguard Small Cap Growth Index Fund
717,531
1.36%
10,790
0.1%
07/31/2018
Franklin Biotechnology Discovery Fund
696,600
1.32%
0
1.71%
03/31/2018
Vanguard Extended Market Index Fund
695,642
1.32%
9,000
0.04%
07/31/2018
| Address |
5500 Flatiron Parkway
Boulder Colorado 80301
United States
|
|
Employees
|
- |
| Website |
http://www.clovisoncology.com |
| Updated |
07/08/2019 |
| Clovis Oncology, Inc. engages in the acquisition, development, and commercialization of anti-cancer agents. Its marketed product, Rubraca, seeks to treat patients with deleterious BRCA mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies. It also has product candidates, namely Rociletinib and Lucitanib. |
